BioSpace News Archive

Milestone Scientific Inc. reported that, following a successful evaluation, it has commenced sales of its CompuFlo® Epidural disposables to UofL Health, a leading academic health system based in Louisville, Kentucky.

Valo Health, Inc. today announced that dosing has commenced in its Phase 2 study - a multi-center randomized, double-blind, placebo-controlled study to evaluate safety and efficacy of oral OPL-0401 in patients with mild, moderate, and severe non-proliferative diabetic retinopathy (NPDR).

Navidea Biopharmaceuticals, Inc. announced today that it has extended the initial rights offering subscription period until 5:00 PM Eastern time on Wednesday, August 24, 2022 and has updated certain pricing information for its rights offering.

Stramsen Biotech Inc. is a Houston, Texas -based Biotechnology Company that currently has eleven new natural plant-based drug candidates for clinical development.

Novavax, Inc. (Nasdaq: NVAX), today announced that New Zealand’s Medsafe has granted expanded provisional approval for Nuvaxovid™ (NVX-CoV2373).

MapLight Therapeutics today announced it has completed its Phase 1 clinical trial evaluating ML-007, the second clinical compound developed using the MapLight platform. ML-007 is an M1/M4 muscarinic agonist that targets circuits thought to be disrupted in neurologic conditions such as schizophrenia and dyskinesia.

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, was recently informed by the Journal of Prevention of Alzheimer’s Disease (JPAD) that there is no convincing evidence to support allegations of data manipulation in a 2020 paper on simufilam co-authored by the Company’s personnel and its science collaborators.

Electromedical Technologies, Inc. (OTCQB: EMED) (“Electromedical” or the “Company”), is pleased to provide its Financial and Operational Highlights for the three and six months ended June 30, 2022.

Biofrontera Inc. announced that PM360, a publication for marketing decision makers in the pharmaceutical, biotech, diagnostics and medical device industries, has named Leslie Hopkins, Associate Director of Marketing, as a Trailblazer Brand Champion in the Dermatology category.

The agreement will enable Ontario based Wellbeings®, who are focused on multi-disciplinary, evidence based, best-practice, patient centred care, to treat their patients with Awakn’s proprietary ketamine-assisted therapy for the treatment of AUD as a co-morbidity for pain.